Inovio Pharmaceuticals Inc. closed $10.99 below its 52-week high ($14.75), which the company reached on April 1st.

Inovio Pharmaceuticals shares were down 20% to $2.99 after hours as the company said it plans to sell stock and accompanying warrants.

(Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today ...

Analyst Stephens covers INOVIO Pharmaceuticals highlighting its diverse clinical pipeline and FDA's consideration of INO-3107 Phase 1/2 trials for Accelerated Approval. Potential as the first non ...

INO), reducing it significantly from $12.00 to $5.00, while maintaining a Neutral rating on the stock. The revised target follows Inovio's recent announcement of its third-quarter financial ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Inovio Pharmaceuticals (INO – Research Report), ...

Shares of Inovio Pharmaceuticals ($INO) slipped nearly 2% on Thursday afternoon ahead of the company’s third-quarter results, with retail sentiment staying bullish ...

Short interest in Inovio Pharmaceuticals Inc (NASDAQ:INO) increased during the last reporting ... on the decline of Inovio Pharmaceuticals's stock. Short interest data is updated every two weeks.

INOVIO (NASDAQ: INO) has announced a stock option grant to a newly hired employee under its 2022 Inducement Plan. The award ...